1. Academic Validation
  2. Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents

Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents

  • Medchemcomm. 2018 Apr 6;9(5):795-811. doi: 10.1039/c8md00022k.
Nazan Inceler 1 Yesim Ozkan 2 Nilufer Nermin Turan 3 Deniz Cansen Kahraman 4 Rengul Cetin-Atalay 4 Sultan Nacak Baytas 1
Affiliations

Affiliations

  • 1 Division of Pharmaceutical Sciences , Department of Pharmaceutical Chemistry , Faculty of Pharmacy , Gazi University , 06330 , Ankara , Turkey . Email: baytas@gazi.edu.tr.
  • 2 Department of Biochemistry , Faculty of Pharmacy , Gazi University , 06330 , Ankara , Turkey.
  • 3 Department of Pharmacology , Faculty of Pharmacy , Gazi University , 06330 , Ankara , Turkey.
  • 4 Cancer Systems Biology Laboratory , Graduate School of Informatics , METU , 06800 , Ankara , Turkey.
Abstract

With the aim of achieving new compounds possessing both anti-inflammatory and antiplatelet activities, we synthesized (E)-3-[3-(pyridin-3/4-yl)-1-(phenyl/sulfonylmethylphenyl)-1H-pyrazol-4-yl]acrylamides, and evaluated their COX-1 and COX-2 inhibitory and antiplatelet activities. Since COX-2 inhibitory and antiplatelet compounds have Anticancer potential, we also screened their antiproliferative effects against three human Cancer cell lines. Compounds 5n, 5p, 5s, 10d, 10g and 10i were determined as dual COX-2 Inhibitor/antiplatelet compounds. Compound 10h appeared to be a compound that exhibited antiplatelet activity without inhibiting the COX Enzyme. Compounds 5h, 10a and 10i were the most effective derivatives which displayed antiproliferative activity against Huh7, MCF7 and HCT116 cells. Particularly, compound 10i, as the compound exhibiting the highest cytotoxic, antiplatelet and COX-2 inhibitory activity, was remarkable.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》